Lipid Disorders
News
PCSK9 Antibodies Safely Cut LDL in Phase II
Major Finding: Patients on the largest Amgen 145 dosage had an average 66% reduction in their LDL cholesterol, and 90% reached their goal LDL...
News
Ranbaxy Recalls Atorvastatin
Conference Coverage
Dalcetrapib Boosts HDL Without Benefiting Patients
Major Finding: After a median 31 months, patients treated with dalcetrapib or placebo showed no significant difference in primary end point events...
Conference Coverage
DPP-4 Inhibitors for Diabetes May Cut Cardiovascular Risk
Major Finding: Patients on a dipeptidyl peptidase-4 inhibitor to treat their type 2 diabetes had a 49% reduction in the composite end point of...
Conference Coverage
In Type 1 Diabetes, Cardiac Measures Improved After Pancreas Transplant
Major Finding: Cardiac morphology and function improved significantly after pancreas-only transplant: Posterior wall thickness and...
Commentary
Statins Sever the Diabetes and Coronary Disease Link
News
Fasting Adds Little to Lipid Profiles
Major Finding: Average LDL cholesterol levels varied by up to 10% by duration of fasting before blood draws.Data Source: A review of lipid results...
News
Insulin Degludec's Long Duration Sways FDA Panel
News
Aliskiren Didn't Protect Heart, Kidneys in Diabetes
Major Finding: After 33 months’ follow-up, 18% of patients taking aliskiren and 17% of placebo patients experienced a serious cardiovascular or...
Conference Coverage
AMG145 Delivers Robust Results for Statin-Intolerant Patients
Major Finding: At 12 weeks, the mean change in LDL cholesterol from baseline with 420 mg AMG145 was –51% as monotherapy and –63% as combination...
News
Practice Changer: CABG Bests Multivessel Stenting in Diabetes
Major Finding: Diabetes patients with multivessel CAD had a 30% lower relative risk of the composite end point of all-cause mortality, nonfatal MI...